Addleshaw Goddard advises Hikma Pharmaceuticals on Ethiopian joint venture
Addleshaw Goddard has advised Hikma Pharmaceuticals plc on a 50–50 joint venture with Sheikh Mohammed Hussein Al Amoudi’s MIDROC Group.
The joint venture, called HikmaCure, establishes a presence for Hikma in the Ethiopian pharmaceutical market. Hikma and MIDROC will invest in HikmaCure in equal proportions and have committed to provide up to $22.3m (£13.8m) each in cash.
The Addleshaw Goddard team was led by corporate finance partner Chris Taylor with support from managing associate Simon Wood.
This is the third corporate transaction Addleshaw Goddard has advised on in Ethiopia in the last two years.
News from Addleshaw Goddard
News from The Lawyer
Briefings from Addleshaw Goddard
Addleshaw Goddard has released the 16 October 2014 issue of its Data Issues Roundup, which provides a weekly round-up of data issues.
This round-up includes costs and unreasonable refusals to engage in ADR and four recent cases considering the refusal by one party to engage in ADR.
Analysis from The Lawyer
Which firms are cutting it in this era of slimline rosters, and who are the GC new brooms making clean sweeps? The Lawyer can reveal all
Could Slater & Gordon achieve its stated aim of becoming a top consumer brand by acquiring Pannone?